Pharmacokinetics, Excretion, and Metabolite Profiling of Leonurine in Rats: Evidence for Extensive Phase II Conjugations
Molecules · 08.06.2026 · 31 (12) · 2002
DOI: 10.3390/molecules31122002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 08.06.2026. Verfasst von Xu Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Medical Supplies Center of PLA General Hospital, Beijing 100853, China. Hauptthemen laut MEDLINE: Gallic Acid. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Leonurine, a bioactive alkaloid from Leonurus japonicus, has attracted considerable pharmacological interest, yet its in vivo disposition remains insufficiently defined. In the present study, the pharmacokinetics, excretion, and metabolic profile of leonurine were systematically investigated in rats after intravenous (IV), oral (PO), and intraperitoneal (IP) administration. A validated LC–MS/MS method was used to quantify leonurine in plasma, urine, and feces, and high-resolution MS was applied for metabolite profiling. Following IV administration, leonurine exhibited rapid systemic disposition, with a half-life of 2.48 h and a clearance of 152 mL/min/kg. Oral exposure was negligible, with an absolute bioavailability of 0.14%, whereas IP administration produced markedly higher systemic exposure (66.6%). Recovery of unchanged leonurine in urine and feces remained low across all dosing routes, with total excretory recovery below 6% of doses. The results indicated that metabolic conversion, rather than parent drug excretion, was the dominant elimination pathway. A total of 30 leonurine-related components were characterized in vivo, including 24 previously unreported metabolites. The metabolic profile was dominated by phase II conjugation, comprising 12 glucuronidated and 12 sulfated metabolites, together with hydrolysis, methylation/demethylation, and other transformation products. Notably, ester bond cleavage was identified as one of the major primary biotransformation routes, and several glucuronide and sulfate conjugates were also formed on hydrolysis-derived fragments. These findings provide a more comprehensive view of leonurine disposition in rats and offer a mechanistic basis for its rapid clearance and limited systemic availability after oral administration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Medical Supplies Center of PLA General Hospital, Beijing 100853, China.
- Senior Department of Traditional Chinese Medicine, Chinese PLA Hospital, Beijing 100853, China.
- Department of Organ Transplantation, The Third Medical Center of PLA General Hospital, Beijing 100039, China.
- School of Pharmaceutical Sciences, Peking University, Beijing 100083, China.
ORCID-Profile: Zhanpeng Shang
Zitieren
APA
Liu, X., Hu, J., Chen, Y., Shi, B., Shang, Z., & Liang, Y. (2026). Pharmacokinetics, Excretion, and Metabolite Profiling of Leonurine in Rats: Evidence for Extensive Phase II Conjugations. Molecules, 31(12), 2002. https://doi.org/10.3390/molecules31122002
Vancouver
Liu X, Hu J, Chen Y, Shi B, Shang Z, Liang Y. Pharmacokinetics, Excretion, and Metabolite Profiling of Leonurine in Rats: Evidence for Extensive Phase II Conjugations. Molecules. 2026;31(12):2002. doi:10.3390/molecules31122002
BibTeX
@article{Liu2026,
author = {Liu, Xu and Hu, Jing and Chen, Yang and Shi, Bin and Shang, Zhanpeng and Liang, Yan},
title = {Pharmacokinetics, Excretion, and Metabolite Profiling of Leonurine in Rats: Evidence for Extensive Phase II Conjugations},
journal = {Molecules},
year = {2026},
volume = {31},
number = {12},
pages = {2002},
doi = {10.3390/molecules31122002}
}
EUVIMED